Atezolizumab with chemotherapy for treating recurrent triple-negative breast cancer

Atezolizumab with chemotherapy is currently in clinical development for the treatment of early
relapsing, recurrent triple-negative breast cancer (TNBC). TNBC is an uncommon form kind of
breast cancer where the tumour cells do not have any of the receptors that are commonly found
in breast cancer. TNBC is often more aggressive and harder to treat compared to other types of
breast cancer. The prognosis for these patients is extremely poor so there is a need to develop
additional treatment options.